Hunter College
97. Li, L. Di, L., Akther, S., Zeglis, B. M., Qiu, W. “Evolution of the Antigenic-Variability vls Locus of the Lyme Disease Pasthogen and Development of Recombinant Monoclonal Antibodies Targeting Conserved VlsE Epitopes” Microbiology Spectrum. Online Ahead of Print (2022). (link)
96. Sarrett, S. M., Rodriguez, C., Rymarczyk, G., Hosny, M., Keinänen, O., Delaney, S., Thau, S., Krantz, B. A.*, Zeglis, B. M. Bioconjugate Chemistry 33(9), 1750 (2022). (link)
95. Rodriguez, C., Delaney, S., Sarrett, S. M., Keinänen, O., Zeglis B. M. “Antibody Engineering for Nuclear Imaging and Radioimmunotherapy” Journal of Nuclear Medicine 63, 1316 (2022). (link)
94. Maitz, C. A., Delaney, S., Cook, B. E., Genady, A. R., Hoerres, R. Kuchuk, M., Makris, G., Valliant, J. F., Sadeghi, S., Lewis, J. S., Hennkens, H. M., Bryan, J. N.*, Zeglis, B. M.* “Pretargeted PET of Osteodestructive Lesions in Dogs” Molecular Pharmaceutics 19, 3153 (2022). (link)
93. Kunihiro, A. G., Sarrett, S. M., Lastwika, K. J., Solan, J. L., Pisarenko, T., Keinänen, O., Rodriguez, C., Taverne, L. R., Fitzpatrick, A. L., Li, C. I., Houghton, A. M., Zeglis, B. M.*, Lampe, P. D.* “CD133 as a Biomarker for an Autoantibody-to-ImmunoPET Paradigm for the Early Detection of Small Cell Lung Cancer” Journal of Nuclear Medicine 62, 1701 (2022). (link)
92. Macpherson, D. S., McPhee, S. A., Zeglis, B. M., Ulijn, R. V. “The Impact of Tyrosine Iodination on the Aggregation and Cleavage Kinetics of MMP-9-Responsive Peptide Sequences” ACS Biomaterials Science and Engineering. In Press (2022).
91. Sharma, S. K., Mack, K. N., Piersigilli, A., Pourat, J., Edwards, K. J., Keinänen, O., Jiao, M. S., Zhao, H., White, B., Brooks, C. L., de Stanchina, E., Madiyalakan, M. R., Hollingsworth, M. A., Radhakrishnan, P., Lewis, J. S., Zeglis, B. M. “ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody” Clinical Cancer Research. In Press (2022). (link)
90. Keinänen, O., Dayts, E. J., Rodriguez, C., Sarrett, S. M., Brennan, J. M., Sarparanta, M., Zeglis. B. M. “Harnessing PET to Track Micro- and Nanoplastics In Vivo” Scientific Reports. 11:11463 (2021). (link)
89. Sharma, S. K., Adumeau, P., Keinänen, O., Sisodiya, V., Sarvaiya, H., Tchelepi, R., Korsen, J. A., Pourat, J., Edwards, K. A., Ragupathi, A., Hamdy, O., Saunders, L. R., Rudin, C. M., Poirier, J. T., Lewis, J. S., Zeglis, B. M. “Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targetd ImmunoPET” Bioconjugate Chemistry. 32, 1255 (2021). (link)
88. Keinänen, O., Nash, A. G., Sarrett, S. M., Sarparanta, M., Lewis, J. S., Zeglis, B. M. “Emerging Radiopharmaceuticals in Clinical Oncology” in Nuclear Oncology: Pathophysiology and Clinical Applications, 3nd Edition. Strauss W., Mariani G., Volterrani, D., and Larson, S. M., eds. Springer: New York, USA, 2022.
87. Imlimthan, S., Khng, Y. C., Keinänen, O., Zhang, W., Airaksinen, A. J., Kostiainen, M. A., Zeglis, B. M., Santos, H. A., Sarparanta, M. “A Theranostic Cellulose Nanocrystal-based Drug Delivery System with Enhanced Retention in Pulmonary Metastases of Melanoma” Small. 2007705 (2021). (link)
86. Sarrett, S. M., Keinänen, O., Dayts, E. J., Dewaele-Le Roi, G., Rodriguez, C., Carnazza, K. E., Zeglis, B. M. “In Vivo Pretargeting Based on Inverse Electron-Demand Diels Alder Click Chemistry” Nature Protocols. s41596-021-00540-2 (2021). (link)
85. Xiao, G., Annor, G. K., Fung, K., Keinänen O., Zeglis, B. M., Bargonetti, J. “Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide” Molecular Pharmaceutics. 18, 338 (2021). (link)
84. Sarbisheh, E. K., Dewaele-Le Roi, G., Shannon, W., Tan, S., Xu, Y., Zeglis, B. M.*, Price, E. W.* “DiPODS: A Reagent for Site-Specific Bioconjugation via the Irreversible Re-bridging of Disulfide Linkages” Bioconjugate Chemistry. 31, 2789 (2020). (link)
83. Keinänen, O., Fung, K., Brennan, J. M., Zia, N., Harris, M., van Dam, E. Biggin, C., Hedt, A., Stoner, J., Donnelly, P. S., Lewis,J. S., Zeglis, B. M. “Harnessing 64Cu/67Cu for a Theranostic Approach to Pretargeted Radioimmunotherapy”
Proceedings of the National Academic of Sciences of the United States of America. 117(45), 28316 (2020). (link)
82. Herth, M. M., Ametamy, S., Antuganov, D., Bauman, A., Berndt, M., Brooks, A. F., Bormans, G., Choe, Y. S., Gillings, N., Häfeli, U. O., James, M. L., Kopka, K., Kramer, V., Krasikova, R., Madsen, J., Mu, L., Neumaier, B., Piel, M., Rosch, F., Ross, R., Schibli, R., Scott, P. J. H., Shalgunov, V., Vasdev, N., Wadsak, W., Zeglis, B. M. “On the Consensus Nomenclature Rules for Radiopharmaceutical Chemistry: Reconsideration of Radiochemical Conversation” Nuclear Medicine and Biology. 93, 19 (2021). (link)
81. Fung, K., Sharma, S. K., Keinänen, O., Long Roche , K., Lewis, J. S., Zeglis, B. M. “A Molecluarly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer”Molecular Pharmaceutics. 17, 3140 (2020). (link)
80. Fung, K., Vivier, D., Keinänen, O., Sarbisheh, E. K., Price, E. W., Zeglis, B. M. “89Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe” Molecules. 25, 2315 (2020). (link)
79. White, J. M., Keinänen, O. M., Cook, B. E., Zeglis, B. M., Gibson, H. M., Viola, N. T. “Removal of Fc Glycans from [89Zr]Zr-DFO-anti-CD8 Prevents Peripheral Depletion of CD8+ T Cells”Molecular Pharmaceutics. 17(6), 2099 (2020). (link)
81. Fung, K., Sharma, S. K., Keinänen, O., Long Roche , K., Lewis, J. S., Zeglis, B. M. “A Molecluarly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer”Molecular Pharmaceutics. 17, 3140 (2020). (link)
78. Ulaner, G. A., Carrasquillo, J. A., Riedl, C., Yeh, R., Ross, D. S., Jhaveri, K., Chandarlapaty, S., Hyman, D. M., Zeglis, B. M., Lyashchenko, S. K., Lewis, J. S. “Identification of HER2-positive metastases in patients with HER2-negative primary breast cancer using HER2-targeted 89Zr-pertuzumab PET/CT” Radiology. 296, 370 (2020). (link)
77. Imberti, C., Adumeau, P., Blower, J. E., Al Salemee, F., Torres, J. B., Lewis, J. S., Zeglis, B. M., Terry, S. Y. A., Blower, P. J. “Manipulating the In Vivo Behavior of 68Ga with Tris(hydroxypyridinone) Chelators: Pretargeting and Blood Clearance” International Journal of Molecular Sciences. 21, 1496 (2020). (link)
76. Jannetti, S. A., Zeglis, B. M., Zalutsky, M. R., Reiner, T. “Poly(ADP-ribose)polymerase (PARP) Inhibitors and Radiation Therapy” Frontiers in Pharmacology. 11, 170 (2020). (link)
75. Pirovano, G., Jannetti, S. A., Carter, L. M. Sadique, A., Kossatz, S., De Souza Franca, P. D., Maeda, M., Zeglis, B. M., Lewis, J. S., Humm, J. L., Reiner, T. R. “Targeted Brain Tumor Radiotherapy Using an Auger Emitter” Clinical Cancer Research. 26, 2871 (2020). (link)
74. Vivier, D., Fung, K., Rodriguez, C., Adumeau, P., Ulaner, G. A., Lewis, J. S. Sharma, S. K., Zeglis, B. M. “The Influence of Glycans-Specific Bioconjugation on the FcgRI Binding and In Vivo Performance of 89Zr-DFO-Pertuzumab” Theranostics. 10(4), 1746 (2020). (link)
73. MacPherson, D. S., Fung, K., Cook, B. E., Francesconi, L. C., Zeglis, B. M. “A Brief Overview of Metal Complexes as Nuclear Imaging Agents” Dalton Trans. 48, 14547 (2019). (link)
72. Keinanen, O. M., Brennan, J. M., Membreno, R., Fung, K. C., Gangangari, K., Dayts, E. J., Williams, C. J., Zeglis, B. M. “Dual Radionuclide Theranostic Pretargeting” Mol. Pharm. 16(10), 4416 (2019). (link)
71: Goos, J. A. C. M., Keinänen O. M., Zeglis B. M., Lewis J. S. “Radiopharmaceuticals in Oncology” in Handbook of Radiopharmaceuticals (2nd Edition) - Methodology and Applications. Scott, P. J. H. and Kilbourn, M. R. Eds. Wiley-Blackwell: Hoboken, 2020 (In Press).
70. Rondon, A., Schmitt, S., Briat, A., Ty, N., Maigne, L., Quintana, M., Membreno, R., Zeglis B. M., Navarro-Teulon, I., Pouget, J. P., Chezal, J. M., Miot-Noirault, E., Moreau, M., Degoul, F. “Pretargeted Radioimmunotherapy and SPECT Imaging of Peritoneal Carcinomatosis Using Bioorthogonal Click Chemistry: Probe Selection and First Proof-of-Concept” Theranostics Online Ahead of Print (2019).
69. Radiopharmaceutical Chemistry; Lewis, J. S., Windhorst, A. D., and Zeglis, B. M. Ed.; Springer: New York, 2019. (link)
68. Membreno, R., Keinanen, O. M., Cook, B. E., Tully, K. M., Fung, K. C., Lewis, J. S., Zeglis, B. M. “Towards the Optimization of Click-Mediated Pretargeted Radioimmunotherapy” Mol. Pharm. 16(5), 2259 (2019). (link)
67. Vivier, D., Sharma, S. K., Adumeau, P., Rodriguez, C., Fung, K., Zeglis, B. M. “The Impact of Fc[gamma]RI Binding on ImmunoPET” J. Nucl. Med. 60(8), 1174 (2019). (link)
66. Davydova, M., Dewaele Le Roi, G., Adumeau, P., Zeglis, B. M. "Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates" Journal of Vis. Exp. 145, e59063 (2019). (link)
65. Membreno, R. M., Cook, B. E., Zeglis, B. M. “Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction” Journal of Vis. Exp. 143, e59041 (2019). (link)
64. Poty, S., Carter, L. M., Mandleywala, K., Membreno, R., Abdel-Atti, D., Ragupathi, A., Scholz, W. W., Zeglis, B. M.*, Lewis, J. S.* “Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma” Clin. Can. Res. 25(2), 868 (2019). (link)
63. Cook, B. E., Membreno, R. M., Zeglis, B. M. “Dendrimer Scaffold for the Amplification of In Vivo Pretargeting Ligations” Bioconjugate Chem. 29, 2734 (2018). (link)
62. Vivier, D., Sharma, S. K., Zeglis, B. M. “Understanding the In Vivo Fate of Radioimmunoconjugates for Nuclear Imaging” J Label. Cmpd. Radiopharm. 1-21 (2018). (link)
61. Adumeau, P., Davydova, M., Zeglis, B. M. “Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability” Bioconjugate Chem. 29, 1364 (2018). (link)
60. Jannetti, S. A., Carlucci, G., Carney, B., Kossatz, S., Shenker, L., Carter, L. M., Salinas, B., Brand, C., Sadique, A., Donabedian, P. L., Cunanan, K. M., Gonen, M., Ponomarev, V., Zeglis, B. M., Souweidane, M. M., Lewis, J. S., Weber, W. W., Humm, J. L., Reiner, T. “PARP-1 Targeted Radiotherapy in Mouse Models of Glioblastoma” J Nucl. Med. 59, 1225 (2018). (link)
59. Membreno, R., Cook, B. E., Fung, K., Lewis, J. S., Zeglis, B. M. “Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Cancer” Mol. Pharm. 15, 1729 (2018). (link)
58. Sharma, S. K., Chow, A., Monette, S., Vivier, D., Pourat, J., Edwards, K. J., Dilling, T. R., Abdel-Atti, D., Zeglis, B. M., Poirier, J. T., Lewis, J. S. “Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models” Cancer Res. 78, 1820 (2018). (link)
57. Adumeau, P., Vivier, D., Sharma, S. K., Wang, J., Zhang, T., Chen, A., Agnew, B. J., Zeglis, B. M. “Site-Specifically Labeled Antibody-Drug Conjugate for Simultaneous Therapy and ImmunoPET” Mol. Pharm. 15, 892 (2018). (link)
56. Poty, S., Membreno, R., Glaser, J. M., Ragupathi, A., Scholz, W. W., Zeglis, B. M.*, Lewis, J. S.* “The Inverse Electron-Demand Diels-Alder Reaction as a New Methodology for the Synthesis of 225Ac-Labelled Radioimmunoconjugates”Chem. Comm. 54, 2599-2602 (2018). *Co-corresponding authors (link)
55. Ulaner, G., Lyashchenko, S. K., Rield, C., Ruan, S., Zanzonico, P. B., Lake, D., Jhaveri, K., Zeglis, B. M., Lewis, J. S., O’Donoghue, J. A. “First-in-Human HER2-targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer”J. Nucl. Med. 59, 900 (2018). (link)
54. Keinanen, O., Fung, K., Pourat, J., Jallinoja, V., Vivier, D., Pillarsetty, N., Airaksinen, A. J., Lewis, J. S., Zeglis, B. M., Sarparanta, M. “Pretargeting of Internalizing Trastuzumab and Cetuximab with a 18F-tetrazine Tracer in Xenograft Models” Euro. J. Nucl. Med. Mol. Imag. Res. 7, 95 (2017). (link)
53. Meyer, J.-P., Kozlowski, P., Jackson, J., Cunanan, K. M., Adumeau, P., Dilling, T. R., Zeglis, B. M.*, Lewis, J. S.* “Exploring Structural Parameters for Pretargeting Radioligand Optimization” J. Med. Chem. 60(19), 8201 (2017). (link) *Co-corresponding authors
52. Altai, M., Membreno, R., Cook, B., Tolmachev, V., Zeglis, B. M. “Pretargeted Imaging and Therapy” J Nucl. Med. 58(10), 1553 (2017). (link)
51. Sharma, S. K., Pourat, J., Abdel-Atti, D., Carlin, S., Piersigilli, A., Bankovich, A. J., Gardner, E. E., Hamdy, O., Isse, K., Bheddah, S., Sandoval, J., Cunanan, K. M., Johansen, E. B., Allaj, V. Sisodiya, V., Liu, D., Zeglis, B. M., Rudin, C. M., Dylla, S. J., Poirier, J. T., Lewis, J. S. “Non-Invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer” Cancer Res. 77(14), 1 (2017). (link)
50. Zeglis, B. M.*, Vugts, D. J.* “ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape” Mol. Imag. Biol. 19, 325 (2017). (link) *Co-corresponding authors
49. Houghton, J. L., Membreno, R., Abdel-Atti, D., Cunanan, K. M., Carlin, S., Scholz, W. W., Zanzonico, P. B., Lewis, J. S., Zeglis, B. M. “Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry” Mol. Cancer Ther. 16(1), 124 (2017). (link)
48. Meyer, J.-P., Adumeau, P., Lewis, J.S., Zeglis, B. M. “Click Chemistry and Radiochemistry: The First Ten Years” Bioconjugate Chem. 27, 2791 (2016). (link)
47. Büchel, G. E., Carney, B., Zeglis, B. M., Eppinger, J., Reiner, T. “A Novel Technique for Generating and Observing Chemiluminescence in a Biological Setting” Journal of Vis. Exp. e54694 (2017). (link)
46. Sarparanta, M., Demoin, D., Cook, B. E., Lewis, J. S., Zeglis, B. M. “Emerging Radiopharmaceuticals in Clinical Oncology” in Nuclear Oncology: Pathophysiology and Clinical Applications. Strauss W., Mariani G., Volterrani, D., and Larson, S. M., eds. Springer: New York, In Press (2016). (link)
45. Abdolreza, Y., Bilton, H., Vito, A., Genady, A. R., Rathmann, S. M., Zainab, A., Janzen, N., Czorny, S., Zeglis, B. M., Francesconi, L. C., Valliant, J. F. “A Bone-Seeking Trans-Cyclooctene for Pretargeting and Bioorthogonal Chemistry: A Proof of Concept Study Using 99mTc- and 177Lu-Labeled Tetrazines” J Med. Chem. Online Ahead of Print (2016). (link)
44. Adumeau, P., Carnazza, K. E., Brand, C., Carlin, S. D., Reiner, T., Agnew, B. J., Lewis, J. S., Zeglis, B. M.“A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer” Theranostics 6(12), 2267 (2016). (link)
43. Büchel, G. E., Carney, B., Shaffer, T. M., Tung, J., Austin, C., Arora, M., Zeglis, B. M., Grimm, J., Eppinger, J., Reiner, T. “Near-Infrared Intraoperative Chemiluminescence Imaging” ChemMedChem. 11(18), 1978 (2016). (link)
42. Cook, B. E., Adumeau, P., Membreno, R., Carnazza, K. E., Brand, C., Reiner, T., Agnew, B. J., Lewis, J. S., Zeglis, B. M. “Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate” Bioconjugate Chem. 27(8), 1789 (2016). (link)
41. Price, E. W., Edwards K. J., Carnazza, K. E., Carlin, S. D., Zeglis, B. M., Adam, M. J., Orvig, C., Lewis, J. S. "A Comparative Evaluation of the Chelators H4Octapa and CHX-A"-DTPA with the Therapeutic Radiometal 90Y" Nucl. Med. Biol. 43(9), 566-576 (2016).
40. Sharma, S. K., Nemieboka, B., Sala, E., Lewis, J. S., Zeglis, B. M. “Molecular Imaging of Ovarian Cancer” J. Nucl. Med. 57, 827-833 (2016). (link)
39. Sharma, S. K., Sevak, K. K., Monette, S., Carlin, S. D., Knight, J. C., Wuest, F. R., Sala, E., Zeglis, B. M.*, Lewis, J. S. “Preclinical 89Zr-immunoPET for High Grade Serous Ovarian Cancer and Lymph Node Metastasis” J. Nucl. Med. Online 57, 771-776 (2016). (link) *Co-corresponding author
38. Adumeau, P., Sharma, S. K., Brent, C., Zeglis, B. M. “Site-Specifically Labeled Immunoconjugates for Molecular Imaging — Part 2: Peptide Tags and Unnatural Amino Acids” Mol. Imag. Biol. 18,153-165 (2016). (link)
37. Adumeau, P., Sharma, S. K., Brent, C., Zeglis, B. M. “Site-Specifically Labeled Immunoconjugates for Molecular Imaging — Part 1: Cysteine Residues and Glycans” Mol. Imag. Biol. 18, 1-17 (2016). (link)
36. Houghton, J. L., Zeglis, B. M., Abdel-Atti, D., Sawada, R., Scholz, W. W., Lewis, J. S. “Pretargeted ImmunoPET of Pancreatic Cancer: Overcoming Circulating Antigen and Antibody Internalization to Reduce Radiation Doses” J. Nucl. Med. 57, 453-459 (2015). (link)
35. Meyer, J. -P., Houghton, J. L., Koslowski, P., Abdel-Atti, D., Reiner, T., Pillarsetty, N. V. K., Scholz, W. W., Zeglis, B. M.*, and Lewis, J. S.* “18F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry” Bioconjugate Chem. 27, 296-301 (2015). *Co-corresponding author (link)
34. Houghton, J. L., Zeglis, B. M., Abdel-Atti, D., Aggeler, A., Sawada, R., Agnew, B. J., Scholz, W. W., Lewis, J. S. “Site-Specifically Labeled CA19.9-Targeted Immunoconjugates for the PET, NIRF, and Multimodal PET/NIRF Imaging of Pancreatic Cancer” Proc. Nat. Acad. Sci. U.S.A. 112(52), 15850 (2015). (link)
33. Zeglis, B. M.*, Brand, C. Abdel-Atti, D., Carnazza, K., Cook, B., Carlin, S., Reiner, T., Lewis, J. S.* “Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics” Mol. Pharm. 25, 3575 (2015). *Co-corresponding author (link)
Memorial Sloan Kettering Cancer Center (Advisor: Jason S. Lewis)
32. Zeglis, B. M., Lewis, J. S. “The Bioconjugation and Radiosynthesis of 89Zr-DFO-Labeled Antibodies” Journal of Vis. Exp. 96, e52521 (2015). (link)
31. Reiner, T., Lewis, J. S., Zeglis, B. M. “Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging” Journal of Vis. Exp. 96, e52335 (2015). (link)
30. Zeglis, B. M., Davis, C. B., Abdel-Atti, D., Carlin, S. D., Chen, A., Aggeler, R., Chen, A., Agnew, B., and Lewis, J. S. “Chemoenzymatic Strategy for the Synthesis of Site-Specifically Labeled Immunoconjugates for Multimodal PET and Optical Imaging” Bioconjugate Chem. 25, 2123 (2014). (link)
29. Daumar, P., Zeglis, B. M., Ramos, N., Divilov, V., Sevak, K. K., Pillarsetty, N., Lewis, J. S. “Synthesis and Evaluation of 18F-labeled ATP Competitive Inhibitors of Topoisomerase II as Probes for Imaging Topoisomerase II Expression” Eur. J. Med. Chem. 86, 769 (2014). (link)
28. Price, E. W., Zeglis, B. M., Cawthray, J., Lewis, J. S., Adam, M., Orvig, C. “What a Difference a Carbon Makes: H4Octapa vs. C3H4Octapa, Ligands for 111In and 177Lu Radiochemistry” Inorg. Chem. 53, 10412 (2014). (link)
27. Wagner, T., Zeglis, B. M., Groveman, S., Francesconi, L.C., Hermann, W. A., Kuhn, F. E., Reiner, T. “Synthesis of the first radiolabeled 188Re N-heterocyclic carbene complex and initial studies on its potential use in radiopharmaceutical applications” J. Label. Cmpd. Radiopharm. 57, 441 (2014). (link)
26. Deri, M., Ponnala, S., Zeglis, B. M., Pohl, G., Dannenberg, J.J., Lewis, J. S., Francesconi, L. C. “An Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)” J. Med. Chem. 57, 4849 (2014). (link)
25. Zeglis, B. M., Emmetiere, F., Pillarsetty, N., Weissleder, R., Lewis, J. S., Reiner, T. “Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid Phase Peptide Synthesis” Chem. Open. 3, 48 (2014). (link)
24. Reiner, T., and Zeglis, B. M. “The Inverse Electron Demand Diels-Alder Click Reaction in Radiochemistry” J. Labl. Cmpd. Radiopharm. 57(4), 285 (2014). (link)
23. Zeglis, B. M., Houghton, J. L., Evans, M. J., Viola-Villegas, N., Lewis, J.S. “Underscoring the Influence of Inorganic Chemistry on Nuclear Imaging with Radiometals.” Inorg. Chem. 53(4), 1880 (2014). (link)
22. Price, E. W., Zeglis, B. M., Lewis, J. S., Adam, M. J., and Orvig, C. “H6phospa-Trastuzumab: A Bifunctional Methylenephosphonate-based Chelator with 89Zr, 111In and 177Lu.” Dalton Trans. 43, 119 (2014). (link)
21. Price, E. W., Zeglis, B. M., Cawthray, J. F., Ramogida, C. F., Ramos, N., Lewis, J. S., Adam, M. J., and Orvig, C. “H4octapa-Trastuzumab: The Application of a Versatile Acyclic Chelate System for 111In and 177Lu Imaging and Therapy.” J. Am. Chem. Soc. 135(34), 12707 (2013). (link)
20. Zeglis, B. M., Sevak, K. K., Reiner, T., Mohindra, P., Carlin, S. D., Zanzonico, P., Weissleder, R., and Lewis, J. S. “A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry” J. Nucl. Med. 54(8), 1389 (2013). (link)
19. Zeglis, B. M., Davis, C. B., Aggeler, R., Kang, H. C., Chen, A., Agnew, B., and Lewis, J. S. “An Enzyme-Mediated Methodology for the Site-Specific Radiolabeling of Antibodies Based on Catalyst-Free Click Chemistry” Bioconjugate Chem. 24, 1057 (2013). (link)
18. Zeng, D.§, Zeglis, B. M.§, Lewis, J. S., and Anderson, C. “The Growing Impact of Bioorthogonal Click Chemistry on the Development of Radiopharmaceuticals” J. Nucl. Med. 54(6), 829 (2013). §Co-first authors. (link)
17. Deri, M. A.§, Zeglis, B. M.§, Francesconi, L. C., Lewis, J. S. “PET Imaging with 89Zr: From Radiochemistry to the Clinic” Nucl. Med. Bio. 40, 3 (2013). §Co-first authors. (link)
16. Zeglis, B. M., Holland, J. P., Lebedev, A. Y., Cantorias, M. V., and Lewis, J. S. “Radiopharmaceuticals for Imaging in Oncology with Special Emphasis on Positron-Emitting Agents” in Nuclear Oncology: Pathophysiology and Clinical Applications. Strauss W., Mariani G., Volterrani, D., and Larson, S. M., eds. Springer: New York, 35-78 (2012).
15. Bailey, G. A., Price, E. W., Zeglis, B. M., Ferreira, C. L., Boros, E., Lacasse, M. J., Patrick, B. O., Lewis, J. S., Adam, M. J., and Orvig, C. “H2azapa: A Versatile Acyclic Multifunctional chelator for 67Ga, 64Cu, 111In, and 177Lu” Inorg. Chem. 51, 12575 (2012). (link)
14. Zeglis, B. M., Mohindra, P., Weissmann, G. I., Divilov, V., Hilderbrand, S. A., Weissleder, R., and Lewis, J. S. “A Modular Strategy for the Construction of Radiometallated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels-Alder Click Chemistry.” Bioconjugate Chem. 6, 424 (2011). (link)
13. Zeglis, B. M., Pillarsetty, N., Divilov, V., Blasberg, R. A., and Lewis, J. S. “The Synthesis and Evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), A PET Radiotracer Designed for the Delineation of Histone Deacetylase Expression in Cancer.” Nuc. Med. Bio. 38, 683 (2011). (link)
12. Zeglis, B. M. and Lewis, J. S. “A Practical Guide to the Construction of Radiometallated Bioconjugates for Positron Emission Tomography.” Dalton Trans., 40, 6168 (2011). (link)
11. Zeglis, B. M., Divilov, V., and Lewis, J. S. “Role of Metalation in the Topoisomerase IIα Inhibition and Antiproliferation Activity of a Series of α-Heterocyclic-N4-Substituted Thiosemicarbazones and Their Cu(II) Complexes.” J. Med. Chem., 54, 2391 (2011). (link)
California Institute of Technology (Advisor: Jacqueline K. Barton)
10. Zeglis, B. M., Kaiser, J. T., Pierre, V. C., and Barton, J. K. “Crystal Structures of a Rhodium Metalloinsertor Bound to an Adenosine-Adenosine Mismatch: General Architecture of the DNA insertion Binding Mode.” Biochemistry, 48, 4247 (2009). (link)
9. Zeglis, B. M., Boland, J. A., and Barton, J. K. “Recognition of Abasic Sites and Single Base Bulges in DNA by a Metalloinsertor.” Biochemistry, 38, 39 (2009). (link)
8. Zeglis, B. M. and Barton, J. K. “Binding of Ru(bpy)2(eilatin)2+ to Matched and Mismatched DNA.” Inorg. Chem. 47, 6452 (2008). (link)
7. Zeglis, B. M., Boland, J. A., and Barton, J. K. “Targeting Abasic Sites and Single Base Bulges in DNA with Metalloinsertors.” J. Am. Chem. Soc. 130, 7530 (2008). (link)
6. Zeglis, B. M., Pierre, V. P., and Barton, J. K. “Metallointercalators and Metalloinsertors.” Chem. Comm., 44, 4565 (2007). (link)
5. Zeglis, B. M. and Barton, J. K. “DNA Base Mismatch Detection with Bulky Rhodium Intercalators: Synthesis and Applications.” Nature Protocols, 2, 357 (2007). (link)
4. Zeglis, B. M. and Barton, J. K. “A Mismatch-selective Bifunctional Rhodium-Oregon Green Conjugate: A Fluorescent Probe for Mismatched DNA.” J. Am. Chem. Soc., 128, 5654 (2006). (link)
The National Institutes of Health (Advisor: Kenner C. Rice)
3. Greiner, E., Boos, T. L., Prisinzano, T. E., DeMartino, M. G., Zeglis, B. M., Dersch, C. M., Marcus, J., Partilla, J. S., Rothman, R. B., Jacobsen, A. E., Rice K. C. “Design and Synthesis of Promiscuous High-Affinity Monoamine Transporter Ligands: Unraveling Transporter Selectivity.” J. Med. Chem., 49, 1766 (2006). (link)
Yale University (Advisor: Robert H. Crabtree)
2. Chianese, A. R., Zeglis, B. M., and Crabtree, R. H. “Unexpected Oxidative C-C- Cleavage in the Metallation of 2-substituted Imidazolium Salts to Give N-heterocylic Carbene Complexes.” Chem. Comm., 19, 2176 (2004). (link)
1. Chianese, A. R., Kovacevic, A., Zeglis, B. M., Faller, J. W., and Crabtree, R. H. “Abnormal C-5 N-Heterocyclic Carbenes: Extremely Strong Donor Ligands and their Iridium(I) and Iridium(III) Complexes.” Organometallics, 23, 2461 (2004). (link)
